1,2,3,4-四氢喹啉-6-甲酸 | 5382-49-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,2,3,4-四氢喹啉-6-甲酸
• 中文别名: 1,2,3,4-四氢基-6-羧酸喹啉；1,2,3,4-四羟基-6-羧酸喹啉
• 英文名称: 1,2,3,4-tetrahydroquinoline-6-carboxylic acid
• 英文别名: 1,2,3,4-tetrahydro-6-quinolinecarboxylic acid
• CAS: 5382-49-0
• 化学式: C₁₀H₁₁NO₂
• mdl: MFCD00957087
• 分子量: 177.203
• InChiKey: ARNALYPZOYPNAF-UHFFFAOYSA-N

物化性质

• 熔点：
  168 °C
• 沸点：
  382.6±31.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)
• 溶解度：
  >26.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

SDS

Name:	1 2 3 4-Tetrahydro-6-quinolinecarboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	5382-49-0

Section 1 - Chemical Product MSDS Name:1 2 3 4-Tetrahydro-6-quinolinecarboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5382-49-0	1,2,3,4-Tetrahydro-6-quinolinecarboxyl	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5382-49-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H11NO2
Molecular Weight: 177.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5382-49-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,2,3,4-Tetrahydro-6-quinolinecarboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5382-49-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5382-49-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5382-49-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢喹啉-6-甲酸 在 palladium-carbon 聚合甲醛 作用下， 以 乙醇 为溶剂， 生成 N-甲基-1,2,3,4-四氢喹啉-6-甲酸
  参考文献：
  名称：

  Heterocyclic esters of rapamycin

  摘要：

  一种具有以下结构的化合物##STR1## 其中R和R.sup.1各自独立地是##STR2## 或氢，R.sup.2是一个杂环基团，可以选择性地被取代；n = 0-6；但是请注意，R和R.sup.1都不是氢，或其药学上可接受的盐，可用作免疫抑制剂，抗炎，抗真菌，抗增殖和抗肿瘤剂。

  公开号：

  US05385909A1
• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 双氧水 作用下， 以 四氯化碳 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.0h， 生成 1,2,3,4-四氢喹啉-6-甲酸
  参考文献：
  名称：

  Palladium(II)-catalyzed heterocyclisation of 8-arylethynyl-1,2,3,4-tetrahydroquinolines: a facile route to 2-aryl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline derivatives

  摘要：

  Dihydropyrroloquinolines have been synthesized reacting 8-arylethynyl-1,2,3,4-tetrahydroquinolines in the presence of palladium(II) chloride catalyst. Heteroannulation has been achieved in good yields and tolerates substituents on the tetrahydroquinoline, including bromo, cyano, and ester. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.02.041

文献信息

• [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014140076A1

  公开（公告）日：2014-09-18

  The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.

  本发明涉及式(I)的新化合物，其中R1为C1-4烷基；R2为C1-4烷基、C3-7环烷基、-CH2CF3、-CH2OCH3或杂环烷基；R3为C1-4烷基、-CH2F、-CH2OH或-CH2O(O)CH3；R4存在时如权利要求1所定义；R5存在时为H、卤素、羟基或C1-6烷氧基；A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)(CH3)-；V为苯基、杂芳基或吡啶酮，其中任何一个可以选择性地被1、2或3个取代基取代；W为CH或N；X为C或N；Y为C或N；Z为CH或N；但W、X、Y和Z中不超过2个为N，含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
• [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2021003295A1

  公开（公告）日：2021-01-07

  The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。
• Synthesis and Characterization of Iron–Nitrogen-Doped Graphene/Core–Shell Catalysts: Efficient Oxidative Dehydrogenation of <i>N</i>-Heterocycles
  作者：Xinjiang Cui、Yuehui Li、Stephan Bachmann、Michelangelo Scalone、Annette-Enrica Surkus、Kathrin Junge、Christoph Topf、Matthias Beller

  DOI：10.1021/jacs.5b05674

  日期：2015.8.26

  and stable core-shell catalysts. In this respect, we present the synthesis and characterization of iron oxides surrounded by nitrogen-doped-graphene shells immobilized on carbon support (labeled FeOx@NGr-C). Active catalytic materials are obtained in a simple, scalable and two-step method via pyrolysis of iron acetate and phenanthroline and subsequent selective leaching. The optimized FeOx@NGr-C catalyst

  纳米催化的一个重要目标是开发灵活有效的方法来制备活性稳定的核壳催化剂。在这方面，我们介绍了由固定在碳载体上的氮掺杂石墨烯壳包围的氧化铁的合成和表征（标记为 FeOx@NGr-C）。通过醋酸铁和菲咯啉的热解和随后的选择性浸出，以简单、可扩展的两步法获得活性催化材料。优化的 FeOx@NGr-C 催化剂在几种 N-杂环的氧化脱氢中表现出高活性。药学相关喹啉的合成证明了这种良性方法的效用。此外，机理研究证明反应通过超氧自由基阴离子（·O2(-)）进行。
• [EN] N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES<br/>[FR] DERIVES DE N-THIAZOLE-2-YLE-BENZAMIDE
  申请人：LUNDBECK & CO AS H

  公开号：WO2005039572A1

  公开（公告）日：2005-05-06

  The invention relates to N-thiazol-2-yl-benzamide derivatives of the formula I in the description wherein the variables are as defined in the claims. The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

  该发明涉及描述中的式I的N-噻唑-2-基苯甲酰衍生物，其中变量如索权中所定义。这些化合物是A2A受体配体，如拮抗剂、激动剂、反向激动剂或部分激动剂，并且在治疗神经和精神障碍中具有用处，其中A2A受体被牵涉其中。
• DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE
  申请人：BRAUN Alain

  公开号：US20090176775A1

  公开（公告）日：2009-07-09

  The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 2c , R 2d , R 3a , R 3b and R 4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11β-HSD1 is involved.

  本发明涉及一种具有以下式（I）的化合物： 其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂合物，其制备、药物组合物以及用于治疗11β-HSD1酶参与的疾病的用途。